Treatment of hepatitis C virus (HCV) infection has been revolutionized with the introduction of pangenotypic, interferon-and ribavirin-free regimens associated with high cure rates and a low side effect profile. Additionally, there is evidence that HCV cure reduces HCV complications, improves patient-reported outcomes and is cost-saving in most western countries in the long term. This is a review of the comprehensive burden of HCV and the value of eliminating HCV infection. With the introduction of the interferon-free all-oral, once a day pill treatment regimen for the cure of HCV, the potential to eliminate HCV by 2030 has become a possibility for some regions of the world. Nevertheless, there are barriers to screening, linkage to care, and treatment in many countries that must be overcome in order to reach this goal. In conclusion, globally, work must continue to ensure national policies are in place to support screening, linkage to care and affordable treatment in order to eliminate HCV.
| INTRODUC TI ON
Hepatitis C virus infection (HCV) affects 71.1 million persons globally which is equal to approximately 1.0% of the world population.
Depending on the country, the prevalence of HCV infection may be concentrated in certain specific groups. [1] [2] [3] [4] [5] In contrast, in other countries, the prevalence of HCV can be very high in the general population. [1] [2] [3] [4] [5] Although the absolute number of HCV-infected individuals is high in Asia, the highest prevalence rates in the general population are reported from the Eastern Mediterranean and the European regions with prevalence rates of two·3% and 1.5%, respectively.
2
Hepatitis C virus infection is self-limiting in about 25% of patients whose HCV RNA in the serum becomes permanently undetectable after the initial infection. However, around 75% of the infected individuals do not clear the virus within 6 months after exposure, and develop chronic hepatitis which can then lead to end-stage liver disease. 1, 2 In fact, the risk of developing cirrhosis is between 10% and 30% within 20 years. 1, 2 Additionally, approximately 399 000 people die each year from hepatitis C, due mostly to cirrhosis and hepatocellular carcinoma (HCC).
1,2
Increasingly, chronic HCV infection is considered a systemic disease which negatively affects clinical, economic and patientreported outcomes (PROs). Clinically, HCV-related cirrhosis can lead to several complications, including decompensated cirrhosis and HCC leading to increased mortality. 3 Additionally, HCV infection impacts a number of organs outside the liver and is responsible for multiple extrahepatic manifestations. Finally, HCV infection can negatively impact PROs through the direct effects on the liver or by affecting extrahepatic organs. 3, 4 These hepatic and non-hepatic consequences of HCV infection are responsible for a tremendous burden on patients and the society. [3] [4] [5] [6] In this review, we provide the summary of a working group meeting which was sponsored by the 
| CLINIC AL OUTCOME S OF H C V INFEC TI ON-THE HEPATI C CON S EQUEN CE S
Hepatitis C virus infection is associated with chronic liver disease, cirrhosis, HCC and liver-related mortality. [6] [7] [8] [9] Among HCV-infected patients, 10%-30% will develop cirrhosis and 1%-5% will develop HCC over 20 years. [5] [6] [7] [8] [9] However, the rate of progression of HCV-related liver disease can be influenced by many factors such as age at the time of infection, gender (male), ethnicity (African American), co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV),
and comorbid conditions such as alcohol abuse, immunosuppression, insulin resistance and superimposed non-alcoholic steatohepatitis (NASH), haemochromatosis or schistosomiasis. 5, 10 Geographical location may also play a role in disease progression.
In the United States (U.S.) and Europe, the rate of progression to cirrhosis ranges between 8% and 24% over a time span of 20-30 years, leading to an annual HCC development rate between 1% and 4%. [11] [12] [13] [14] However, in Japan, the rate of progression to cirrhosis is higher ranging between 30% and 46% with an annual rate of progression to HCC ranging between 5% and 7%. 15 Hepatitis C virus-related mortality is mainly attributed to HCC and complications of cirrhosis. 9, 11 In the United States, deaths associated with HCV are more likely to be caused from decompensated cirrhosis, 8 while in Japan, the most common cause of HCV-related death is HCC. 15 It is important to note that development of gastro-esophageal varices and other decompensating events is associated with an additive increase in the risk for mortality. 8 In fact, the cumulative probability of decompensation is 5% at year one, increasing to 30% at 10 years after diagnosing cirrhosis. Once decompensated cirrhosis occurs, 5-year survival of HCV patients is ≤50%. 8 In contrast, 3, 5
and 10-year survival rates of compensated cirrhosis related to HCV are estimated to be 96%, 91% and 79%, respectively.
11-14
This high burden of HCV-liver disease globally has made HCV one of the leading indications for liver transplantation (LT). 9 In one study from the United States, 52 540 or 41% of patients listed in 2010 was related to HCV-liver disease. 16 Using birth cohorts, patients born in 1951-1955 accounted for the highest frequency of being listed for HCV. Additionally, there was a fourfold increase in new registrants with HCV and HCC which occurred between 2000 and 2010 in the 1941-1960 birth cohorts. It was concluded that there will be an increasing demand for LT as a result of HCV-HCC as these birth cohorts continue to age placing an increasing demand on a limited organ pool. 16 In addition, the presence or absence of viraemia affects mortality. Patients with detectable HCV antibodies and HCV RNA have almost eight times higher liver-related mortality rate than those with detectable antibodies and negative HCV RNA. Furthermore, allcause mortality among HCV RNA-positive patients was more than double as compared to HCV RNA-negative cases, with mortality being higher for those who developed a non-liver-related disease in addition to being HCV RNA-positive. 17 These data suggest that HCV continues to pose a significant clinical burden related to cirrhosis, HCC, and as an indication for LT.
These hepatic complications of HCV will continue to cause significant clinical burden in many countries in the next few decades.
| CLINI C AL OUTCOME S OF H C V INFEC TI ON-THE E X TR AHEPATI C CONS EQUEN CE S
There is strong evidence that HCV causes a number of important extrahepatic manifestations (EHM). 18 A recent analysis found that the prevalence of auto-immune diseases in HCV-infected individuals included vasculitis (5%-15%), arthralgia-myalgia (25%) and sicca syndrome (10%-15%), while serum auto-antibodies were found in 10%-40%. In addition, about 15% of HCV-infected patients had symptomatic mixed cryoglobulinemia (MC) and 35% were at increased risk of developing lymphoma.
19-22
In addition to these data, another systematic review and metaanalysis summarized the data on nine most common EHM-associated In summary, both hepatic and extrahepatic consequences of HCV infection constitute important clinical outcomes that can affect patients' mortality and morbidity.
| PATIENT-REP ORTED OUTCOME S OF H C V INFEC TI ON
Patient-reported outcomes are considered the surrogates for understanding the impact of a disease and its intervention on patients'
experience. Accordingly, health-related quality of life (HRQL), which is a type of PRO, is defined as "a multi-dimensional concept that includes domains related to physical, mental, emotional and social functioning. HRQL goes beyond direct measures of population health, life expectancy, and causes of death, and focuses on the impact health status has on quality of life." In addition to HRQL, work and activity impairments in HCV patients have been assessed using a self-administered questionnaire.
Studies of HCV patients have suggested impairment in work productivity is found primarily in the presenteeism aspect of work productivity. In studies from the United States, absenteeism does not seem to be negatively impacted by HCV possibly since patients' inability to work can mean the loss of associated health insurance and other benefits provided by their employer.
28,29
In addition to depression and neuropsychiatric disorders, fatigue is highly prevalent in HCV and has been assessed by fatiguespecific PRO measures. 30, 31 In one study that assessed predictors of depression in patients with different chronic liver diseases, fatigue was found to be a major predictor of depression in HCVinfected patients but not in those diagnosed with chronic hepatitis B or non-alcoholic liver disease. 27 Another study reported that 61%
of HCV-infected patients complained of overwhelming fatigue with fatigue having the strongest negative impact on patients' HRQL.
30
In addition to HRQL, work productivity can also be negatively affected by fatigue. 31 Although the underlying mechanism is not fully known, high baseline serum levels of interferon-γ and low levels of chemokine (C-C motif) ligand 2 may be associated with persistent fatigue after HCV cure. 32 These data suggest that fatigue is common in HCV patients negatively affecting their HRQL and work productivity and can persist after HCV cure. Although there are some potential associations for underlying mechanisms, further research is needed.
In addition to fatigue, other variables associated with impairment These findings were consistent across subgroup of HCV patients such as those on opioid substitution therapy, those who were coinfected with HIV, and across different regions of the world.
50-52
Nevertheless, there are limited data from real world practices reporting PRO data outside clinical trials. 53 Yet, as more HCV patients are treated and cured, further studies should be published using real world data to highlight the positive effects of the new all-oral interferon-free direct antiviral agents.
| HE ALTH ECONOMI C S OF H C V INFEC TI ON
Health economics of HCV can provide different assessments related to the economic burden, cost-effectiveness, and budgetary impact of HCV infection and its treatment.
54-62
The majority of studies on the HCV economic burden estimated the direct cost of liver disease [inpatient care, outpatient visits, prescription drugs, medical devices, rehabilitation costs and long-term employment rates among HCV-infected persons (U.S.) are low (54% vs 62% at the national level), but when employed, HCV-infected patients are more likely to incur increased rates of absenteeism (lost hours of work) and presenteeism (decreased productivity while at work). As a result, the estimated annual costs due to work productivity impairment as a result of HCV have been estimated to be $7.1 billion in the United States. 65 In Europe, the annual cost of lost work has been projected to be 2.6 billion €. 23, 30 Lost work productivity costs have also been reported for Taiwan, South Korea, Hong Kong and Singapore to be $0.5 billion. 66 
| THE VALUE OF ACHIE VING SUS TAINED VIROLOG I C RE S P ON S E AF TER TRE ATMENT OF H C V INFEC TI ON
Since the approval of the new direct acting antiviral agents, the cost of these regimens has been debated despite the data showing high cure rates and excellent side effect profile. [67] [68] [69] In order to fully appreciate the benefit of the new antiviral regimens for HCV, one must expand the debate beyond the "cost of the regimen" to include the "value of HCV cure." The value of cure places the clinical and quality outcomes of HCV treatment in the context of the costs associated with delivering these outcomes. To address the value of HCV cure, a recent study used a model that combined clinical outcomes with quality of life and costs of treating HCV genotype (GT)-1 patients in the United States. In fact, the study concluded that treating these patients could potentially result in a "value" worth $111 billion. These cost savings were especially evident for the HCV GT1 patients with cirrhosis. 67 Others have also investigated the value of cure from different angles related to additional clinically relevant issues. Using a conservative model with 90% SVR-12 rates, treating patients without any fibrosis rather than waiting for fibrosis to progress was cost effective. 70 In addition, a significant reduction in non-liver-related mortality can be observed in patients without fibrosis. 72 Others have compared the new regimens to the older interferon-based regimens and documented significant economic gains by treating all HCV patients with the new regimens. [71] [72] [73] In addition to assessing the improvement in cost per qualityadjusted life (QALY) saved, it is also appropriate to assess the cost savings that could potentially be associated with HCV cure by assessing the reductions in complications such as HCC and decompensated liver disease. A recent study looked at the economic gains obtained when treatment leads to a reduction in cases of HCC and decompensated cirrhosis in Japan. 74 Using a decision analytic
Markov state-transition model, a hypothetical cohort of HCV GT 1b
Japanese patients was treated with approved all-oral DAAs. QALYs gained were also monetized using a willingness to pay threshold of 4-6 million Japanese Yen. 74 The study documented significant cost savings related to avoidance of HCC and decompensated cirrhosis. 74 Another aspect of the comprehensive benefits of HCV cure must address the gains associated with the reduction in EHM and improvement in HRQL and work productivity loss due to HCV infection. In this context, achieving SVR with antiviral therapy has been shown to lead to a 61% reduction in the risk of stroke in HCV patients. 83 Additionally, after 5 years of follow-up post-treatment, HCV patients who were cured experienced four times lower rates of cardiovascular events as compared to those who were not cured (3.5% vs 12.3%). 84 Furthermore, there has been additional evidence supporting the positive impact of HCV cure in reducing chronic kidney disease and its associated costs. 85 Similarly, there has been evidence supporting the benefits of HCV cure leading to better glycaemic control in HCV-infected patients. 19, 86 These and other data suggest that treatment of HCV to achieve high SVR rates not only leads to improvement in clinical outcomes (cirrhosis and mortality) but also to substantial cost savings related to a reduction in both hepatic and extrahepatic complications of HCV infection.
In addition to the economic benefits related to the reduction in clinical complications of HCV infection, the monetary value of improvement of HRQL and work productivity after HCV cure are also substantial. Noted previously, HCV infection leads to impairment in work productivity. 87, 88 While older regimens containing interferon, temporarily reduced work productivity, 89, 90 regardless of treatment, achieving SVR led to improvement in work productivity. 91, 92 More recently, an analysis of a large cohort of HCV patients treated with new DAA regimens provided strong evidence that SVR was not only associated with improvement of HRQL but also substantial gains in the presenteeism aspect of work productivity, both potentially leading to economic gains. 92 In summary, it is clear that HCV is associated with high cost burden related to liver disease, EHM, quality of life impairment and worker productivity losses. In contrast, the cure of HCV can be associated with improvement of all these cost outcomes maximizing the value delivered by the new antiviral regimens.
| COMPARING COS TS A SSO CIATED WITH H C V TRE ATMENT WITH COS TS OF TRE ATING OTHER CHRONIC D IS E A S E S
Investigators have also reported the cost of curing HCV in comparison with the costs of treating other chronic diseases.
In 2013, the cost of cure for treating a patient with HCV GT1 was estimated to be between $82 000 and $91 000. 75 This cost was substantially smaller than the per patient lifetime costs of treatment for type 2 diabetes mellitus ($109 000-$114 000), HIV ($268 000-$427 000), rheumatoid arthritis ($165 000-$187 000), breast cancer with metastases ($136 000) and relapsing/remitting multiple sclerosis ($433 000-$459 000). 75 Since 2013, there have been significant reductions in the cost of HCV regimens due to market competition, discounts, use of generics and other contracting agreements which have made the cost of these regimens more favourable. Nevertheless, it is important to remember that the cost of treating HCV is upfront while the cost of other chronic diseases is spread overtime. This has important budgetary impact for payers with short-term perspectives.
However, the societal perspective with it long-term view must be adopted so national policies will support the initial investment for the long-term gains of reducing HCV-related complications and their associated costs.
| ECONOMI C S OF H C V SCREENING
If HCV cure is cost effective, then there must be a strategy to effectively screen for HCV and link the infected patients to care.
Nevertheless, it is important to note that initiating a screening program is expensive and implementation can be complex. Several In the context of comprehensive burden of HCV, the value of antiviral regimens must not only consider the clinical improvement after SVR but also improvement in PROs and economic gains.
Considering all these components, new antiviral regimens represent a good value to the society. Although cost of treatment regimens has important budgetary implications, long-term societal benefit of curing HCV is quite clear.
In the context of eliminating HCV by 2030, the most important challenges are to identify innovative and cost-effective approaches to optimize the continuum of care from screening and linkage to care. 95 This can be achieved by national, regional and global policies that will provide evidence about the comprehensive benefit of HCV cure, worldwide.
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